ストックスクリーナーアプリを入手
32.32
0.62%
0.20
プレマーケット:
32.40
0.08
+0.25%
Celldex Therapeutics Inc (CLDX) 最新ニュース
Barzolvolimab leaves 64% of CSU patients angioedema-free 7 months after dosing - Stock Titan
New Celldex antibody depletes mast cells in first human test - Stock Titan
Celldex reports positive phase 1 data for CDX-622 antibody By Investing.com - Investing.com Canada
Celldex Presents Positive Phase 1 Results for CDX-622, a Novel Bispecific Antibody for Mast Cell Depletion and TSLP Inhibition at EAACI Annual Meeting - Quiver Quantitative
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting - Yahoo Finance
Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus - Sahm
Celldex to present barzolvolimab, CDX-622 data at EAACI congress By Investing.com - Investing.com Canada
Celldex to present mast cell targeting drug data at European congress - StreetInsider
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress - Stock Titan
UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating - marketscreener.com
CLDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Celldex closes $345 million stock offering - Investing.com
CLDX News | CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) - ChartMill
Wall Street analysts see a 76.42% upside in Celldex (CLDX): Can the stock really move this high? - MSN
Celldex Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Celldex Therapeutics (CLDX) Edges Lower Amid Consolidation Near Key SupportReversal Trade - newsline.com
ELVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $38 to $67 - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) - Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 - Stock Titan
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - Eastern Progress
Celldex Therapeutics stock (US15117B1035): Wells Fargo raises price target to $54 - AD HOC NEWS
Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup - ChartMill
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $54 - Moomoo
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals - Yahoo Finance
State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics - Stock Titan
The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones - Sahm
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67 - Moomoo
RLAY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals - Sahm
Celldex Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Celldex: Q1 Earnings Snapshot - theheraldreview.com
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Celldex filled two late-stage hives trials 6 months early - Stock Titan
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, vs. FactSet Est of $795K - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) widens loss while funding late-stage barzolvolimab trials - Stock Titan
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, Vs. FactSet Est of $795K - Moomoo
Celldex (NASDAQ: CLDX) Q1 loss grows while $345M raise funds pipeline - Stock Titan
Celldex Reports First Quarter Financial Results and Provides Corporate Update - ChartMill
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial (NASDAQ:CLDX) - Seeking Alpha
FMR LLC reports 5.6% stake in CellDex Therapeutics (CLDX) - Stock Titan
MSN Money - MSN
Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapies and 80+ Companies Advancing Next-Generation Biologics and Small Molecules | DelveInsight - Barchart.com
Celldex earnings on deck as barzolvolimab Phase 3 nears readout By Investing.com - Investing.com Australia
Vanguard Capital Management (NASDAQ: CLDX) reports 3.45M shares; 5.17% stake - Stock Titan
Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com UK
[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):